Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.03 AUD
Change Today +0.001 / 4.17%
Volume 1.5M
As of 12:59 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

cellmid ltd (CDY) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - A$0.04
52 Week Low
04/8/15 - A$0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLMID LTD (CDY)

Related News

No related news articles were found.

cellmid ltd (CDY) Related Businessweek News

No Related Businessweek News Found

cellmid ltd (CDY) Details

Cellmid Limited develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia. It offers MK ELISA, a sandwich enzyme immunoassay in a 96 well plate format for measuring midkine levels in human serum samples. The company’s pipeline of products include CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of inflammatory and autoimmune diseases; CMK103, a recombinant for use in cardiac ischemia. It also develops and sells FGF-5 inhibitor, an over the counter treatments to alleviate excessive and abnormal hair loss and reestablish the natural hair growth cycle. The company is based in Sydney, Australia.

cellmid ltd (CDY) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$434.5K
Compensation as of Fiscal Year 2014.

cellmid ltd (CDY) Key Developments

Cellmid Limited Announces Executive Changes

Cellmid Limited announced that the Board of Directors has appointed Mrs. Lucy Rowe as Company Secretary. Mrs. Rowe has worked in the financial services industry for the last fifteen years and currently holds and has held Company Secretarial positions with other listed companies. The Board also announced the resignation of Mr. Nicholas Falzon and Ms. Jillian McGregor as joint Company Secretaries, effective as of March 31, 2015.

Cellmid Limited Announces Unaudited Consolidated Earnings Results for the Half Year Ended December 31, 2014

Cellmid Limited announced unaudited consolidated earnings results for the half year ended December 31, 2014. For the period, the consolidated company reported revenue was AUD 685,183 against AUD 1,529,074 a year ago. Loss before income tax was AUD 1,988,499 against AUD 475,479 a year ago. Loss for the half-year attributable to owners of the company was AUD 1,000,119 against profit of AUD 242,029 a year ago. Diluted loss per share was 0.14 cents against earnings of 0.04 cents a year ago. Net cash used by operating activities was AUD 981,191 against AUD 574,326 a year ago. Payments for purchase of plant and equipment were AUD 7,003 against nil a year ago.

Cellmid Limited Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Cellmid Limited Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDY:AU A$0.03 AUD +0.001

CDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CDY.
View Industry Companies

Industry Analysis


Industry Average

Valuation CDY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.0x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLMID LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at